Philips is leading a major new European project to develop drug delivery technologies that could significantly impact the treatment of cancer and cardiovascular disease. By allowing drugs to be delivered to disease sites via the patients bloodstream and then activated by focused ultrasound pulses, the SonoDrugs project aims to maximize the therapeutic efficiency and minimize the side effects of drug treatments for cancer and cardiovascular disease. The project, which involves a total of fifteen industrial partners, university medical centers and academic institutions from throughout the European Union (EU), will run for four years and has a budget of €15.9 million, €10.9 million of which is being funded under the EUs 7th Framework program.
Philips Localized Drug Delivery Development - Sonodrugs
Previous post: A Primer on Pacira Pharma Seeking Alpha
Next post: Fission
You must log in to post a comment.